Kolexia
Clement-Filliatre Lauriane
Hématologie
Cabinet libéral
Épinal, France
68 Activités
132 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Myélome multiple Lymphome T Lymphome malin non hodgkinien Syndrome de compression médullaire Récidive tumorale locale Plasmocytome Délétion de segment de chromosome

Industries

Janssen
12 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
10 collaboration(s)
Dernière en 2023
B3TSI
4 collaboration(s)
Dernière en 2020
Edimark
4 collaboration(s)
Dernière en 2022

Dernières activités

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.
Annals of hematology   10 juin 2023
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.
Haematologica   01 janvier 2023
Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study
Annual Meeting Abstracts 2022   15 novembre 2022
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.
Haematologica   01 juillet 2022
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood   21 juillet 2021
MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA (MEITL): CLINICO-PATHOLOGICAL ANALYSIS OF A MULTICENTER EUROPEAN COHORT
16th International Conference on Malignant Lymphoma, Virtual Edition, 18–22 June, 2021   17 juin 2021
044 | MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA (MEITL): CLINICO-PATHOLOGICAL ANALYSIS OF A MULTICENTER EUROPEAN COHORT
16th International Conference on Malignant Lymphoma, Virtual Edition, 18–22 June, 2021   09 juin 2021
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods.
Leukemia   07 juin 2021
Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study
Blood   05 novembre 2020
Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts
Blood   05 novembre 2020